Oncostatin M (OM), which shares functional similarity and structural homology to leukemia inhibitory factor (LIF) and interleukin-6 (IL-6), functions as a potent growth factor for AIDS-associated Kaposi's sarcoma-derived cells (AIDS-KS cells 
Introduction
Kaposi's sarcoma (KS)' is a multicentral proliferative lesion of unknown etiology and unclear pathogenesis (1) . The most common form of KS is frequently associated with HIV infection (AIDS-KS) (2) and with immune suppression due to other causes (3) . KS is an unusual neoplasm with unique features: a high incidence of spontaneous remission, rapid occurrence of multifocal lesions, and lack of metastasis (4) . KS lesions also have a complex histology characterized by a high degree of neovascularization, edema, and proliferation of spindle-shaped cells (KS cells) (5) . Development of AIDS-KS lesions has been reported to consist of multiple steps and interactions of several diverse cytokines (6) (7) (8) (9) , suggesting that KS is not a real tumor but rather a cytokine-mediated proliferative disease. Recently, our group and others reported that a growth regulatory protein, oncostatin M (OM), is a potent mitogen for AIDS-KS cells in culture. Hence, OM may play an important role in the initiation and/or progression of AIDS-KS lesions (10) (11) (12) .
However, little is known of OM receptor sites on AIDS-KS cells, through which OM exerts its growth-stimulating activity. Characterization of OM receptor sites on AIDS-KS cells will provide a better understanding of possible roles of OM in growth regulation of these cells and pave the way toward development of new drugs.
OM, a 30-kD glycoprotein, was originally identified from activated human T cells and a differentiated histiocytic leukemia cell line, based on the potential to inhibit the growth of melanoma cells (13) (14) (15) . Subsequently, OM was characterized as a growth regulator for certain tumor-and non-tumor-derived cell lines. Its pleiotropic biological activities encompass stimulation or suppression of pathways leading to differentiation or proliferation, and induction of other cellular target genes (16) (17) (18) (19) . Several groups reported that OM is a member of a cytokine family that includes leukemia inhibitory factor (LWF) and interleukin-6 (IL-6), because OM shares structural homology and functional similarity to LWF and to . Recently, it was proposed that LIF and OM bind with high affinity to the same receptor (LIF/OM receptor), which consists of a signal transducing subunit for LIF and IL-6 (gpl30) and a LIF binding subunit (LIF receptor a-subunit) (24) . The roles of these subunits on the LIF/OM receptor in OM binding and its signal transduction have yet to be determined, but the overlapping biological activities of these cytokines may be explained by their sharing of the LWF/OM receptor. In contrast, several other biological responses have been reported to be exclusively induced by OM (16, 17) , a finding that suggests existence of an OM-specific receptor and its importance in OM-specific signaling. We asked whether AIDS-KS cells carry a LIF/OM receptor or an OM-specific receptor. gpl30 was reported to be capable of binding OM with low affinity (24) (25) (26) . If OM-specific biological responses correlate with expression of the OM-specific receptor, it needs to be determined if the OM-specific receptor includes gpl30 as a binding subunit and/or a signal transducting subunit.
Miles et al. reported that IL-6 is also a growth factor for AIDS-KS cells, determined by using the antisense oligonucleotide for the coding region of IL-6 (27). However, we obtained evidence that the growth-stimulating response of AIDS-KS cells is not induced by either LIF or IL-6. The fundamental question is whether the difference in biological response among OM, IL-6, and LIF arises from the specificity in receptor expression or relates to differences in postreceptor pathways on AIDS-KS cells. We Binding assay. AIDS-KS cells were grown to confluence (2.5 X 104 cells/well) in duplicate (0.5 ml) in 24-well plates. The plates were washed three times with binding buffer (DME containing 50 mM BES, pH 6.8, and 0.1% BSA) and incubated at 370C for 4 h in binding buffer to allow for endocytosis of cellular receptors that bound OM from the culture medium. After three additional washes, the cells were incubated with various titrated concentrations of 35S-labeled OM starting at 4 nM in a volume of 0.2 ml of the same buffer. Binding reactions were carried out for 3 h at room temperature. Nonspecific binding was measured in the presence of 100-fold excess of unlabeled OM. The specific binding was calculated by subtracting nonspecific binding from total binding (duplicate determinations). At the end of the incubation period, the cells were washed four times with binding buffer to remove unbound 35S-labeled OM and then trypsinized. Cell-bound radioactivities were measured in Aquasol (New England Nuclear, Boston, MA) using a scintillation counter. Variation between duplicate determinations was generally less than 10%. The dissociation constant and an average number of binding sites per cell were calculated by Scatchard plot analysis using saturation binding data (28) . Data from binding experiments with AIDS-KS cells were also analyzed using the LIGAND computer program (29) . For competition binding studies, the unlabeled cytokines were serially titrated, starting at a concentration of 0.5 nM. 355-labeled OM was added at a constant concentration of 0.5 nM. 35S-labeled and unlabeled cytokines were mixed before adding to AIDS-KS cells. Binding reactions were incubated for 4 h at room temperature in a volume of 0.2 ml of binding buffer. Binding assays for LIF and IL-6 on KS cells followed the same protocol as the OM-binding assay.
Cross (28) was constructed from saturation binding data obtained in Fig. 1 A  (Fig. 1 B) . The plot was a curvilinear curve and best fit by a curve generated for a two-binding-site model, which revealed two affinity classes of OM receptors on AIDS-KS-USC22 cells. "S-labeled OM bound to KS cells with a higher affinity at lower "S-labeled OM concentrations. Using a two-receptor model, dissociation constants (Kd values) of the two hypothetical sites of 7±1 pM (high affinity) and 720±60 pM (low affinity) were obtained for AIDS-KS-USC22 cells. These estimates of affinity on AIDS-KS cells were in the range of estimates for other OM responsive cells (24, 30) . Average numbers of high and low affinity receptors of OM were 8,700±300 and 340,000±100,000 per cell, respectively; the values are high when compared with receptor levels on other OM-responsive cells (24, 30 These data show that biological effects ofOM on AIDS-KS cells are achieved at partial receptor occupancy, which means that KS cells have a high proportion of spare receptors forOM. For many cytokines, this difference was noted between the concentration required to achieve maximal biological response and that required for maximal binding (31) . The concentration of35S-labeledOM giving a half-maximal biological response corresponded to 55-60% saturation of the high affinity receptor and 1-4% of low affinity receptor.Our findings indicate that occupancy of a high affinity receptor more than a low affinity receptor is important for growth-stimulating activity ofOM. There were no significant differences among data obtained from experiments done with three different isolates of AIDS-KS cells. Therefore, it seems likely that OM-induced stimulation of AIDS-KS cell growth correlates with expression of the high affinity receptor forOM.
Specificity of biological activity and binding of OM to AIDS-KS cells: lack of growth stimulating effects and binding properties of IL-6 and LIF on AIDS-KS cells.OM is structurally and functionally related to LIF and IL-6 (20-23). Previous work revealed that IL-6 as well asOM have growth stimulating effects for AIDS-KS cells (27). To determine whetherOM, LIF, and IL-6 share the activity as an AIDS-KS cell mitogen, AIDS-KS growth assays for three isolates of KS cells (KS-USC22, KS lOB, and K53 cells) were performed using recombinant hu- man OM, LIF, and IL-6 at various concentrations. As shown in TableI, growth stimulation of AIDS-KS cells was exclusively observed in response toOM and not to LIF or IL-6. None of the three different isolates used in this study exhibited significant growth augmentation by LIF or by IL-6. In addition, no growth-inducing effects byIL-6 were observed on 14 isolates derived from different patients (Table II) . A possible explanation for theOM-specific biological activity for AIDS-KS cell growth may be the existence of anOM-specific receptor and the absence of LIF and IL-6 receptors on AIDS-KS cells. To examine this possibility, binding experiments on three isolates of KS cells using35S-labeled LIF or IL-6 performed (Fig. 3) .
Compared with binding of35S-labeledOM, neither3"S-labeled LIF nor IL-6 bound to AIDS-KS cells, a finding that shows the lack of LIF and IL-6 receptors on AIDS-KS cells. Thus, the specificity in binding probably contributes to theOM-specific growth stimulating effect on AIDS-KS cells. (Fig. 4) . Binding of 35S-labeled OM was displaced by unlabeled OM, which again indicated the presence of a specific receptor for OM and the absence of the LIF/OM receptor on AIDS-KS cells. As expected from the lack of any detectable binding of 35S-labeled LIF and IL-6 to AIDS-KS cells (Fig. 3) unit (putative ,Q-subunit of the OM-specific receptor). Considering the relative molecular weight of this species, it is unlikely that this species includes two molecules of gpl3O. While the significance of the 50-kD species is not clear, similar observations were noted for other OM responsive cells (29) . This band might represent another subunit of the OM-specific receptor.
AIDS-KS cells express gpJ30 mRNA, but not mRNA for LIF receptor a-subunit or IL-6 receptor a-subunit. The expression of specific mRNA was demonstrated by the appearance of PCR amplification products (Fig. 8) . PCR amplification, using ds cDNA for four isolates of AIDS-KS cells (KS-USC22, KS lOB, KS3, and KS14), revealed considerable amounts of expression of gpl3O mRNA and only scanty amounts of PCR products for the LIF receptor a-subunit or the IL-6 receptor a-subunit were observed. Similar results were also obtained with Northern hybridization (data not shown). These findings mean that neither the LIF/OM receptor nor the IL-6 receptor is expressed on AIDS-KS cells. In addition, the results agree with data showing the lack of any binding of LIF and IL-6, since these a-subunits are reported to serve as binding subunits in their respective receptors.
Discussion
Thoma et al. (34) suggested the existence of two different types of the high affinity receptor for OM. Type I receptor (LIF/OM receptor) binds both OM and LIF, which appears to consist of two subunits: the LIF receptor a-subunit and gpl30 (24) . The existence of the LIF/OM receptor may explain overlapping biological responses of LIF and OM. Type II receptor is an OM-specific receptor, the existence of which may agree with findings that several biological responses are exclusively induced by OM but not by LIF (16, 17) , although the biological relevance and molecular structure of the OM-specific receptor have not been determined. To investigate whether AIDS-KS cells carry the OM/LIF receptor of the OM-specific receptor, or both, we characterized OM receptor binding sites on AIDS-KS cells and found that AIDS-KS cells express the OM-specific receptor, but not the OM/LIF receptor, as the functional high affinity binding site for OM: (a) OM, but not LIF, can elicit a growth-stimulating response for AIDS-KS cells (Table I) (32, 33) . Several studies showed that gpl30 is shared with IL-6 and LIF as a common signal transducer and affinity converter of their receptor, although gpl30 alone cannot bind either LIF or 32) . LIF and IL-6 also have individual binding subunits (a-subunits), which form low affinity receptors. Association of gpl30 to the individual binding subunits is required for high affinity binding to the respective cytokines and for signaling of biological activities. Recent studies indicate that gpl30 can bind OM with low affinity (24, 25) . In addition, the LIF/OM receptor consists of gpl30 and LIF receptor a-subunits (24) . However, it has not been determined if the OM-specific receptor includes gpl30 as an essential component for OM binding and/or signaling. Here, we found that (a) anti-gpl30 antibodies can block the growth-stimulating effect of OM on AIDS-KS cells (Fig. 5) ; (b) the binding of OM to AIDS-KS cells is abolished by anti-gpl30 antibodies (Fig. 6) ; (c) OM binding species detected in cross-linking experiments are blocked by anti-gpl30 antibodies (Fig. 7) ; and (d) the transcript for gpl30 is highly expressed in AIDS-KS cells, as observed in PCR amplification (Fig. 8) . Because (Fig. 3) ; and (c) PCR amplification and Northern blot analysis revealed that the 11L-6 receptor a-subunit was not expressed in four representative KS cell isolates (Fig. 8) . Moreover, we observed that anti-IL-6 antibody had no effect on proliferation of AIDS-KS cell (data not shown), although KS cells produce and secrete 11L-6 (12) . If expression of the IL-6 receptor a-subunit can be induced on AIDS-KS cells, the disparities observed between these studies can be explained by the differential expression of the 11L-6 receptor a-subunit. In a previous study (27), N521J cells, which did not proliferate in response to IL-6 in our culture conditions, may have been exposed to a stimulator(s) for expression of the 1L-6 receptor a-subunit. However neither the IL-6 nor LIF/OM receptor. The lack of binding of these cytokines to KS cells can explain failure to activate postreceptor pathways for signal transduction. OM was reported to be a major growth factor for rabbit vascular smooth muscle 1 Figure 8 . Detection of transcripts for gpl3O, LIEF receptor a-subunit, and IL-6 receptor a-subunit in AIDS-KS-USC22, -KS3, and -KS1OB cells. PCR amplification: equal amounts of double strand cDNA generated from poly (A)+ RNA of four isolates of AIDS-KS cells were subjected to gpl3O-specific, LIEF receptor a-subunit-specific, and IL-6 receptor a-subunit-specific PCR amplifications using paired primers, respectively. RNA integrity and the efficiency of cDNA synthesis were confirmed by PCR amplification, using a human /-actin-specific primer (Clontech, Palo Alto, CA (17) . Because the origin of KS cells was suggested to be a vascular SMC progenitor ( 12) , the similarity in growth response between AIDS-KS cells and SMCs is intriguing. We found that anti-gp 130 antibodies can completely block OM-induced AIDS-KS cell growth (Fig. 5) . KS has been reported to be a proliferative disease induced by several cytokines, which are produced and secreted by AIDS-KS cells (6) (7) (8) . A strategy for producing human monoclonal antibodies in mice has been described (37) , and such mice should permit the development of human monoclonal antibodies with therapeutic potential. Anti-gp 130 antibodies may prove to be a potential therapeutic drug for KS. 
